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Eugene Redmond:
I think that the sessions have been extremely
interesting and provocative. It would be a shame to
end the meeting without an opportunity to raise
further questions, and to tie some issues together
between the various sessions, such as relationships
between the clinical and basic issues. There are
many interesting loose ends, perhaps related to
neural transplantation in general or to specific
issues raised in the various sessions, that it would
be useful to try to tie together. At the same time,
because we have a large audience and hopefully
many of you have important things to say, we are
going to set some ground rules for the discussion
that will give everybody an opportunity to speak.
Therefore, we have chosen some specific topics as
a way of beginning the discussion, and then we will
open the discussion to the floor. We are going to
ask the people who are speaking to limit
themselves to 2 minutes so that everyone or nearly
everyone can get an opportunity to speak.
The first issue in which several people have
expressed a significant interest, is a continuation of
the discussion concerning the design of clinical
trials, and what do we need to do next to move the
field forward. I have had a request from Patrick
Aebischer to start that discussion.
Patrick Aebischer:
Several important questions have arisen during
the course of today’s interesting sessions. One of
our major problems is the interpretation of clinical
results. There are deficiencies in controls and
ethical reasons prohibit the use of sham operations
that might provide the best results. We may,
however, be able to devise a system that would
improve the current situation and would facilitate
the comparison of results. I found it particularly
disturbing that at the end of this afternoon I had to
make up my mind on a very subjective basis, partly
because all the groups used different techniques,
different patient populations, varying ages of
donors and different implant sites, and also utilized
different surgical techniques and evaluations. Some
groups also use cryopreservation. Under these
circumstances, it is very difficult to draw any
meaningful comparisons, especially when the
number of patients is three or four. I therefore
believe that there is a need to coordinate
experiments to allow better evaluations and
ultimately arrive at some clear conclusions.
Regarding the problem of evaluation, I noted that at
least one study made an attempt to use non-
operated patients as controls. Even if the numbers
are small, it might be important to use this kind of
study in a comparison, and to increase their
number. Another important method was the use of
blind evaluation. If I understand correctly, one or
two groups tried to evaluate their patients
"blindly", and this is certainly a very important and
fundamental issue.
Finally, two small points. We have another
neurosurgical alternative for the treatment of
Parkinson’s disease, that is, lesions. As you know,
Mahlon Delong’s work /2/ now suggests that it
might be possible to lesion the subthalamic nucleus
and obtain a striking improvement, at least in the
MPTP monkey model. The neurosurgical
community is considering trials of this procedure in
human patients. Could clinical lesion trials of this
type be compared to transplants in a rational
fashion?
The people who presented it may be able to
explain a little more clearly this last point. In the
one patient that died there seemed to be no
surviving cells. All PET scan data, however,
suggest that there is survival of the transplanted
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cells. Has there perhaps been an improvement in
the resolution or hardware of PET scans, so that we
could be misled just by an improvement in the
technology?
Barry Hoffer:
Would someone like to comment on any or all
of Dr. Aebischer’s questions?
Curt Freed:
We are not exactly starting from a blank piece
of paper here. The results of experiments in rats
and the related experiments in the monkey have
been quite strong. Experiments in rats that have
included controls suggest that dopamine cell
transplants produce effects better than adrenal cells,
at least without nerve growth factor. The fetal age
of rat cells suitable for transplantation is a very
narrow and well-defined stage of development.
These results from animals have been at the heart
of the planning process that we have used. The
group from Lund has proceeded in the same way,
although I don’t want to speak for someone else.
Our conclusions have also been supported by
monkey experiments. We are using PET scans
prior to surgery to demonstrate that the caudate is
in relatively good shape and the putamen has a
severe fluorodopa uptake defect. Based on the
studies by Kish, Hornykiewicz and coworkers/10/,
who have measured dopamine depletion in
Parkinson patients, it looks like the putamen is the
best target for transplantation. Targets can be
individually chosen for each patient by using PET
scans; in other words if fluorodopa uptake looks
normal in the caudate, this would indicate that it is
not necessary to use that as a target for
transplantation. While the sprouting phenomenon
observed after large lesions of the caudate is
interesting, no one has provided evidence that
sprouting occurs in the putamen after stereotaxic
implants. Thus, the fluorodopa uptake data most
likely show growth of fibers from the fetal
dopamine cells. We would argue that experiments
that are not using 6-8 week gestation human
embryos, and which are not putting the tissue in the
putamen are not going to be successful.
Patrick Aebischer:
It would be irrational to claim that rats and
primates do not yield good data. The animal data
do not, however, prove the validity of the human
results. The problem arises when you have to scale
up to humans. You are then dealing with a much
larger structure. I think that it is important to design
these studies so that they can stand on their own. It
is difficult for those of us not doing clinical trials to
draw any conclusions. To put it bluntly, should you
not coordinate your clinical trials, so that you are
no longer looking at 20 variables but less variables
which are better controlled?
Don Gash:
My question follows up on Dr. Aebischer’s
comments. How far along are the groups doing
clinical studies in terms of adopting a uniform set
of standards? As I recall, in the transplant meeting
that was held in Lund several years ago, a
committee was formed to set standards for
evaluating patients. These standards have been
published /11,12/. Are the groups doing clinical
transplants following those standards?
Olle Lindvall:
The Core Assessment Program for Intraeerebral
Transplantation, that is, the "CAPIT", has been
published in a book from the Lund meeting/9,11/
and in Movement Disorders /12/. Several groups
are now following CAPIT. In Europe we have
organized a Network for Intracerebral
Transplantation and Restoration called
"NECTAR". A major task for NECTAR is to
coordinate clinical trials with neural grafting in
Europe. All groups in NECTAR will use CAPIT
for evaluating their patients before and after
transplantation.
One point that Dr. Aebischer brought up was
related to PET scans. We have experience over
several years with PET scans using the same
machine in exactly the same way. We have
definitely not seen improvement of fluorodopa
uptake in all patients, and we have not seen
improvement in all parts of the striatum.
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Ignacio Madrazo:
In relation to the clinical effect caused by the
lesion, we have the experience of having used
different kinds of grafts; so we have patients that
have received fetal transplants, co-transplants, and
adrenal transplants. The time course of evolution
for every group of patients is completely different.
So, we can clearly state that the clinical response is
related to the grafts, because they have a
completely different course of clinical evolution in
the different kinds of grafts.
Scientists are calling on the clinicians to get
organized. I will also call on scientists to get
organized, because I have heard a lot of differences
in the results of different groups in different labs.
That’s something that happens in science at all
levels, so I think that it can also happen in clinics.
Patrick Aebischer:
Should we compare transplant studies to lesion
studies, especially those following Mahlon
Delong’s studies /2/? I know that several groups
have started to lesion the globus pallidus internal
(GPI), and are thinking about lesioning the
subthalamic nucleus. Could we not compare these
procedures in clinical trials?
Edward Hitchcock:
Those interested in the lesion trials will almost
certainly use the CAPIT scheme, so there will be a
regularity and uniformity of approach, in which
case the lesions can be compared to transplantation
studies. As long as we all do the same assessments,
it will be all right it does not have to be the same
group doing it which is the whole point of the
CAPIT scheme.
Olle Lindvall:
It is important to state that, even if from the
neurobiologist’s point of view it is extremely
exciting that we can restore neuronal circuits in the
brain, the main clinical question regarding neural
transplantation is whether and how much the
patients get better. If you treat patients, it is your
responsibility to test and compare different new
possible approaches in a similar way. In my
opinion the lesion data are clearly interesting,
though this strategy has not been conclusively
shown to be clinically valuable.
Juan J. Lopez.Lozano:
To me the crucial point at this time in the field
of neural transplantation is, after searching among
the audience, I have the feeling that we are losing
our audience among neurologists. I think it is
secondary to the way that we have conducted
neurotransplantation and clinical studies. The
problem of the lack of credibility of the results
obtained in humans lies in several important
factors, particularly as mentioned before. I think
the situation of neurotransplantation in Parkinson’s
disease from the neurologic point of view is filled
with serious difficulties. People from different
countries have been using different techniques,
different donor tissues, in different types of
Parkinson’s patients. All of these differences occur
because of the lack of using common protocols or
follow-up.
So, all of us are speaking our own language but
nevertheless we are all getting good results. I can
not understand why, using different kinds of
tissues, in different people and using different
follow-ups let us say using adrenal medulla or
fetal mesencephalon we are getting such similar
results. There are also puzzling differences in the
time course of the clinical changes. I notice that
some people using fetal ventral mesencephalon are
getting good results two months after surgery, and
for other groups the changes require 24 months.
Using adrenal medulla, improvement sometimes
lasts for two months and in other cases lasts 40
months. I would like somebody to explain to me
how this can be possible.
Patrick Aebischer:
To be the Devil’s advocate, I would like to draw
your attention to the small improvements that are
observed with the various procedures and tissue
types used. I would then be worried about
something called the placebo effect.
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Don Gash:
There is also the possibility of common
mechanisms underlying recovery, if people are
seeing very similar effects. Now, from this
symposium, I am wondering if we could have some
comments on the differences in the degree of
recovery seen using adrenal medulla versus
substantia nigra grafts. The other day, there were
several groups who described results of co-graft
trials. If Ray Watts is here, perhaps he could talk
about using the co-graft approach and how
promising those results have been. While a placebo
effect is one possibility, those are other alternatives
which are best studied in non-human primate
models. Trophic factors stimulating residual host
dopaminergic pathways, for example, might
provide for a common mechanism underlying
functional recovery in both adrenal medulla and
fetal tissue graft recipients.
Roy Bakay:
I think that there is a feeling among many of us
not directly involved with clinical fetal grafting
investigations that we are unsure of the degree of
improvement in these studies. If you look at the
reports from everyone who presented today, from
the first patient to the last patient, there has been a
remarkable evolution. None of the investigators is
still using the same techniques as on the first
patient. The investigators are changing things,
moving things around, and in each case they are
doing something different. We must recognize this
as an evolving process, and there is not a
"technique" that can be applied on a large scale.
One way to look at this question is to ask how
many of us out here would ask one of these
investigators to operate on our mother if she had a
severe case of Parkinson’s disease. am not sure if
there are a lot of people in the audience who are
ready to make that decision before more studies are
performed.
Ultimately a multicenter controlled study will
be needed, but before that can be considered we
have to develop a surgical technique that we can all
agree is truly effective. The only way we can get to
that point is to be able to compare the results of
different groups in different countries using
different techniques through use of the CAPIT
protocol /11,12,20/. Only by making the data
complete, accurate, reliable and comparable can we
compare results directly and not have to go through
a series of indirect analyses. There is a big
difference between a pharmacologic study and a
surgical study. Surgical studies always go through
this kind of evolution to refine a technique before
implementing a randomized study or a controlled
study. Even so, you can never randomize in the
same way as a drug study. There are a lot of
reasons for this, which I won’t get into, but the
reasons should be obvious.
Curt Freed:
Roy, at the same time I like the idea that we
have the CAPIT set of standards, the fact that
Parkinson’s disease is variable means that there
also has to be enough data on each individual
patient to say that those measurements mean
something in that particular patient. If you see a
patient at isolated intervals, you get very little
information, so you would have to say we need 50
CAPIT studies per patient, or something like that.
Roy Bakay:
The CAPIT standards deal with these issues of
how many evaluations you need, how close
together, and that sort of thing. Those factors must
be considered in designing any study. The CAPIT
recomendations are for the minimum requirements
and the greater the number of pre-operative
measures the better the assessment of the patient’s
severity and variability of symptoms.
Tom Freeman:
think the critcisms that there should be more
unification in methods is a little severe at this point.
For a number of reasons, there are about 15
different variables that could influence the success
of transplantation trials. It is healthy to try to
approach this as each individual investigator sees
fit, based on their own experience and their own
laboratory data. It is premature to say that any one
particular method is optimal, since no one has had
an overwhelming success at curing all or even most
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symptoms of Parkinson’s disease in the clinic, or in
animals for that matter.
Another issue that I think is being neglected is
that there seem to be at least two different
mechanisms that may be involved clinically, both
of which may correct the symptoms of Parkinson’s
disease. In some cases, the graft may not have
surviving dopaminergic neurons but may induce a
trophic response in the host brain. It is also possible
that clinical improvement may be obtained by
having optimal survival of neurons that reinnervate
the brain. I think that investigators should be clear
as to which of these two strategies they are trying
to optimize. Transplantation of fetal nigral tissue
using techniques that do not produce surviving
grafts in the laboratory, under the premise that it
will create a neuronal hook-up of new circuits, is
not particularly fair to the patients. If induction of
trophic effects is the goal, there are several other
types of tissues which are far safer, easier and more
effective to use and may produce the same end
result. Thus, we should attempt to assess
beforehand what we are trying to achieve with our
transplants.
Barry Hoffer:
Let’s take one more comment on this topic and I
guess Dr. Sladek, that means you are going to get
the last word.
John Sladek:
I am glad Dr. Freeman raised that point because
I think that we may be unduly harsh on ourselves,
even though the objective of a scientist is to be
self-critical. In fact, that is what research is all
about, a great variation in design, approaches and
techniques. Often usefully, and sometimes not so
usefully, there are also differences in
intrepretations but that is also what the purpose of
this meeting is about. In the United States, our own
government, in its infinite wisdom, chose not to
fund this kind of research and I think that, had they
chosen to do so, we might be sitting here after a 5
year coordinated clinical trial with more
standardized approaches and more standardized
interpretations. At the present level of knowledge,
however, the lack of a coordinated clinical trial is
not necessarily bad and I think the kind of self-
analyses and critical analyses we are having will
clearly lead the field to a very positive endpoint.
I would add only one point of minor
disagreement regarding reversing all the signs and
symptoms in any of the patients. In addition to the
fine studies that were presented today, I think the
study by Dr. Widner and colleagues in MPTP
patients /21/ is probably the one that allows the
clearest interpretation; after all, those are patients
with a non-progressive form of parkinsonism.
These MPTP patients more closely parallel the
condition seen in the animal models that we have
used, particularly the non-human primates. There
we have seen several years of an exceptional level
of improvement that is undoubtedly due to the
survival of dopamine nerve cells from the grafted
fetal neuroblasts. I hope we are not too hard on
ourselves.
Barry Hoffer:
That is a good note on which to close the first
part of the discussion. Let us now move on to a
second topic that a number of people have talked
about informally, and which may be appropriate for
this round table. That is, we have focused on
Parkinson’s disease in particular and a few other
diseases during the several days of this meeting,
but what about other diseases? What kinds of
diseases have we not discussed so far, or discussed
only briefly, where transplantation of nerve cells
might be of importance. Does anyone have any
thoughts about that?
Ignacio Madrazo:
I don’t have thoughts, I have cases. We have
done already two cases of Huntington’s disease.
The first one is a patient now followed for more
than one year after surgery and who has obtained a
moderate benefit from surgery. She is still
improving after one year. The second case was just
done very recently. So, that is a new approach, and
a different disease application of transplantation.
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Oile Lindvall: William Freed:
There are a number of neurological disorders
where there could be a potential usefulness of the
neurografting techniques. From the clinical point of
view, it is of course a dilemma for the doctor
because, in many of these disorders, we have no
treatment at all, and the symptoms are very severe.
Nevertheless, in most of these disorders, there is no
scientific basis for clinical trials even in desperate
cases. In my opinion, the only disorder besides
Parkinson’s disease where presently one could
motivate clinical trials is Huntington’s disease.
Huntington’s disease is a fatal disorder, with
progressive dementia. The patients die within 10 to
15 years, and there is no treatment. The lack of
adverse effects in the Parkinsonian patients
implanted with fetal dopamine cells, the evidence
for growth, survival and function of the grafts in
the human brain, as well as the importance of even
a minor symptomatic improvement in Huntington’s
disease by neurografts would help to justify the
first clinical studies with implantation of fetal
striatal neurons into the striatum in Huntington’s
disease. However, in contrast to Dr. Madrazo, I
don’t think that we are at the stage yet when such
studies should be initiated. There are a number of
technical and scientific problems that we must
solve before we can start even the first clinical
trials in Huntington’s disease. The animal
experimental data are very promising: there is good
evidence that striatal grafts can survive in the
ibotenic acid-lesioned striatum, that they are at
least partly anatomically and functionally
integrated into the host neuronal circuitries, and
that these grafts can improve cognitive and motor
deficits. However, we know very little about how
much tissue we should implant, what is the optimal
donor age, and other technical aspects of critical
importance for a clinical application.
There is also a major drawback at present in that
we don’t know how we shall assess cognitive and
motor function in the Huntington’s patients before
and after transplantation. Furthermore, it is critical
that we have methods to assess graft survival in
these patients. When these problems have been
solved, I think that we can justify clinical trials
with neural grafting in a few patients with
Huntington’s disease.
Apparently, Jackie Sagen is not here, but she
might want to say something about her data. The
clinical trials in patients with chronic pain that she
has described/17/are extremely interesting and I
think that continued work along these lines is
certainly justified.
Aside from actual clinical trials per se, another
issue that might be worthwhile to discuss is what
other diseases potentially could provide
applications for transplantation in the future. One
of the diseases for which a very good case could be
made, it seems to me, is epilepsy. In the case of
epilepsy, I am not suggesting in any sense that
clinical trials should be done now. However, it
seems to me that this is a good possibility for the
future. The abnormality can be localized
anatomically and it originates from small areas of
the brain. One of the major obstacles in epilepsy
may be that the animal models are not adequate or
are not sufficiently similar to human epilepsy.
Would anyone care to comment on that perhaps?
Olle Lindvall:
We have been working with transplantation in
experimental epilepsy for 7 years and have good
evidence that neural grafts can suppress epileptic
phenomena in the brain /1,13/. In our model
system, we have used kindled seizures which
resemble temporal lobe epilepsy in humans. We
implant noradrenergic neurons and can suppress
the development of seizures in the kindling model
/1,13/, which may suggest clinical applications.
However, it has not yet been shown that grafts can
have also an anticonvulsant effect on established
seizures.
Also, we have only been able to show the
antiepileptogenic effect if we first damage the
intrinsic noradrenaline system. That is a problem,
because there are several forms of human epilepsy,
and it is not known if any of them is linked to a
deficiency in the intrinsic noradrenaline system.
Thus, it is unclear whether our transplantation data
obtained so far have any clinical relevance. We are
now looking at other types of cells as well, e.g.
GABA producing ones. I would strongly argue
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against any clinical trials with grafting in epilepsy
at the present stage.
Roy Bakay:
You have to look at the severity of the disease and
the severity of the proposed treatment. More
desperate diseases require more desperate attempts
at treatment. For a glioblastoma patient who is
going to die within a year, there is a tremendous
amount that can be done experimentally because
the risk of the procedure can be balanced by the
risks of dying from the disease. For someone with a
disease in which they are going to live 20 or 30
years, the risks of any investigative procedure must
be low and the experimental data need to be very
compelling before you enter into surgical trials.
I think there are really only two other diseases
where grafting techniques might be applied to
humans in the near future; one is the cancer pain
that Jackie Sagen’s group presented/17/, and the
other would be in Huntington’s disease /cf.
6,9,14,19/. In both cases, the patients die in a
relatively short period of time and we don’t have
adequate therapy. We must avoid the mistakes that
were made early on in Parkinson’s disease, where
we grafted adrenal tissue into numerous patients
and only later found that it generally didn’t survive
and only worked for a short period of time. For
diseases that run a benign course we need to do a
great deal of animal investigation, exactly as Dr.
Lindvall was describing earlier. I think that there is
absolutely no reason to start clinical trials for the
other diseases discussed today such as epilepsy. It
is important to remember that the animal models
are not the disease. We need to understand the
pathophysiology of these diseases and the
mechanism of graft function before applying this
technology to "benign diseases".
Richard Bunge:
If we are to develop a catalog of potential
transplantation applications in neuronal loss
diseases, I think it should be mentioned that, at this
meeting, there have been a number of rather
remarkable papers about the success of replacing
lost somatic motor neurons in the spinal cord. One
approach has involved introducing fetal tissue into
regions of the spinal cord depleted of its normal
motor neuron population. In work from France
from Drs. Horvat and Peschanski /8,15/, these
implanted motor neurons have been successfully
guided to nearby muscle by nerve bridges. This
work provides evidence that transplanted motor
neurons in spinal cord in experimental animals,
especially rats, can be guided to successfully
innervate skeletal muscle. Another more extreme
approach to this kind of injury, and to motor
neuron disease in particular, is to actually place
motor neurons in the peripheral nerve near a
denervated muscle. The purpose in this case is to
provide absent neuromuscular innervation with the
hope of driving these isolated transplanted motor
neurons by functional electrical stimulation to
attain functionally useful contraction /5/. In
summary, I think there have been early but
promising developments in the possibility of
replacement of the somatic motor neuron.
Helen Hodges:
I think another case where it might be possible
to develop transplants for human therapeutic use is
after heart attack. There are animal models that
mimic very exactly the interruption of blood flow
to the brain and also result in focal hippocampal
damage. This sort of damage has been identified in
heart attack victims. In fact, about 20 percent of
people who survive heart attacks are found to
suffer from very severe memory deficits. I think
what some clinicians could be doing at the moment
is building up very accurate pictures of the kind of
memory deficit and the type of cell loss that occurs
following heart attack, so that animal models that
mimic these same patterns of damage could be
developed. We could thus look at the effects of
transplanting particular cell types. For instance, we
have found the CA1 cell type to be an important
factor in improving memory performance of
animals with CA1 cell loss following ischemia. I
think that ischemia-induced injury is an area where
clinicans could do a lot of preparatory work while
animal models are being developed.
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Barry Hoffer:
Let us now move on to a final topic for general
discussion that some people brought up informally
over the last few days. We started to see glimmers
of this around the time of the Third Intenational
Meeting in Cambridge and a bit earlier, and it has
really grown very impressively to maturity here.
Perhaps not full maturity as yet, but adolescence
certainly. This is the application of genetic
engineering and immortalization techniques to cells
that are to be transplanted. Perhaps we could now
have some comments about that.
Richard Robbins:
There are a number of very important issues to
consider when dealing with these kinds of
approaches for cell transplantation. Obviously, one
of the most important is that many of the genes that
are introduced in order to help cells divide are in
the category of oncogenes, and these can actually
induce a condition of transformation. Such
transformed cells may have anywhere from a small
to a large capacity to continue to divide in the
central nervous system. The development of, for
instance, temperature-sensitive oncogenes such as
those described by Ron McKay and co-workers at
this meeting/4/is a significant advance in trying to
overcome this problem. Another category of genes
that don’t normally induce a transformed
phenotype, called immortalizing genes, have begun
to be explored as a possible way to turn a switch on
in a cell to make it divide. Such immortalized cells
may continue to produce their own native factors or
biologically active molecules. Genes such as the
adenorviral E1A gene are an example. There are
some new genes coming down the pike that might
not have the transforming potential, and could
potentially be useful for development of cell lines.
I think that one of the other general approaches
that might need to be considered carefully here is
whether or not we can simply transplant cells that
have been modified to overproduce one growth
factor or one neurotransmitter in an unregulated
way, as opposed to implanting cells that have a
neuronal phenotype and may be able to make
appropriate synaptic connections and release either
proteins or small neurotransmitters in a regulated
way.
A major issue that one should consider when
trying to create cell lines, is that there are two
fundamentally different approaches. You can start
with the cell that you want and add on gene that
helps that cell divide, hopefully changing its
phenotype as little as possible. Alternatively, you
can take cells that can be genetically manipulated
quite easily, and introduce the gene, for instance,
for tyrosine hydroxylase, to try to get that cell to
make dopamine. I think we are obviously going to
have to demonstrate that any cell that makes a
certain factor can be transplanted not only into
rodents but primates with a great deal of safety
before we will be able to approach our institutional
review boards or human safety committees to
convince them that we will be able to put these
cells into a human and have absolutely no chance
of forming a tumor.
Paul Carvey:
This a general observation. I see a lot of people
doing very nifty things with gene transplantation---
it is a marvelous field. Nonetheless, I am always
the individual who asks the question---how far
does the substance diffuse? I see a lot of
individuals who are trying to develop things that
may not be practical because the substances they
are trying to make don’t diffuse far enough from
what is essentially a point source. So I think that it
is important that you should establish these
fundamental principles before developing a
protocol to engineer something. If you make it and
implant it into the brain, can it diffuse far enough to
do any good?
Edward Baetge:
The ultimate cells for neural transplantation
may be those that can naturally give rise to specific
differentiated phenotypes and be propagated
continuously in culture. There are now a number of
neuroepithelial progenitor cells which have been
immortalized using SV40 or Myc retroviral
transgenes as recently described by Ron McKay
and co-workers /4/ and Connie Cepco and co-
workers /3/. Although these cells appear to
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differentiate after in vivo transplantation, it remains
to be determined what true long-term in vivo
potential they have and whether the immortalizing
transgenes they express are safe for prolonged in
vivo use. An alternative cell might have the
properties of a neural stem cell, giving rise to both
neurons and glia but also capable of continuous
propagation in vitro without the use of
immortalizing or transforming genes. As described
earlier today, Sam Weiss and Brent Reynolds
/16,18/provided evidence for such a cell that was
capable of being continuously grown in vitro and
differentiated into a number of neuronal and glial
cell types. Such cells are unmodified and might
provide a plentiful transplantation cell source
assuming they could mainta,.’,a their potential for
differentiation upon transplantation or treatment
with various mitogenic or trophic factors. Much
work remains to determine the full potential for the
in vitro/vivo generation of differentiated CNS cell
types, but for the first time we are able to
continuously culture neuroprogenitor cells which
should provide for rapid progress in this area.
Fred Gage:
Another way to look at the idea of gene transfer
from the central nervous system is to take it out of
the context, if we could for the moment, of the
clinical setting. There are other reasons why one
would want to introduce genes into the central
nervous system. Traditionally, the approach we
have had in these meetings has not been just to
address diseases, but also to use transplantation as a
methodology to understand something about the
brain. In that context, I think the delivery of
individual genes, either somatically through the use
of transplanted cells or directly through direct gene
delivery, is one way of more specifically asking
questions about how specific proteins or
transmitters function within the central nervous
system. To that end, we are at the early stages of
this methodology. There are at least 10 questions
that have been raised just by the last two speakers
and I can think of 100 more that are necessary to be
addressed, not for any kind of clinical application
but even in terms of utilizing this as a tool. But I
would say that from what we have seen in this
meeting in the last few days, there have been
probably 15-20 new applications of gene delivery
in the central nervous system as a method of
looking at regenerative responses and release of
transmitters.
While there are a lot of questions that remain to
be answered, I think that what we are seeing is the
birth of a field which will help us to address more
specifically the role that transmitters and trophic
factors play in the central nervous system. If we
think about it that way, rather than immediately
trying to think about how we can apply this to a
clinical setting, we might be able to resolve some
of the fundamental issues first, such as what cell
type to use, and ways of achieving long term
regulatable gene expression, before we start
designing things specifically for their clinical
applications.
Phiilipe Horrellou:
I would like to add some comments to the
previous ones. As you know, genetic engineering
for intracerebral transplantation is a new field.
What we have achieved so far is the use of genetic
tools to produce and deliver neurotransmitters or
growth factors after gene transfer to cells for
transplantation. In our efforts to compensate for
degenerative processes, for the time being, we have
at best been able to deliver the molecules though
diffusion from the grafted cells. There are a number
of tools and experimental conditions that are now
being approached in order to improve these
methods to obtain specific and regulated release
from neurons, such as immortalized neuro-
epithelial cells developed, for instance, by Ron
McKay/4/. Beside genetic modification of cells for
transplantation, direct gene delivery into neurons is
emerging with new vectors. Such vectors, for
instance those illustrated by the methods which
were very nicely described by Joseph Glorioso in
this meeting/7/, may soon be available. We are still
at a starting point and very few applications of
these vectors have been presented. However, we
would like to remove the viral genes which are
present in these vectors that might induce side
effects. I think that there is a requirement for major
improvements in the genetic engineering systems
before we can go in a clinical direction. In
conclusion, gene transfer to the brain is a starting
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field and major improvments are taking place. It
requires considerable effort to develop these tools
for clinical applications, both in term of efficiency
and in terms of safety.
Jens Zimmer
If I may say a few words, I find it extremely
fascinating in this meeting to see that cells that are
normally in the brain can be taken out,
immortalized, and then can actually be put back
into the brain again by using transplantation as a
tool. In the adult rat brain, within 15 days such
cells can transform into genuine CA3 pyramidal
cells if you put them in the hippocampus,
neocortical pyramidal cells when you put them in
the neocortex, or they can be granule cells when
you put them in the cerebellum. With other cell
lines, glial cells may be formed. I am really looking
forward to the meeting in Paris, because I think that
we are at a stage that we will soon see great
advances and refinement in the techniques.
Going back to the clinical issue, I would say
that in many of the cases where we do not know the
mechanisms of a disease, we nonetheless see that
certain nerve cell types degenerate. After cerebral
ischemia, the CA1 pyramidal cells in the
hippocampus are, in particular, susceptible. I think
that in two years time in Paris, we may see cell
lines that when introduced into the brain, into the
CA1 area, will transform into CA1 pyramidal cells.
Moreover, a very interesting thing is that the adult
brain seems to have instructions, or environmental
conditions, that will make these cells differentiate
and perhaps even form and this is where basic
research comes in the right connections. So, in
that sense I am very optimistic about the prospects
for this methodology. With refinements in
techniques, and also with further clarification, we
may see large advances in cell engineering and
development. Many of these we may have
predicted, but now in some cases we know for sure
what is possible.
Richard Robbins:
I would just like to extend that thought by
saying that I think that some of the newer
molecular biological approaches for understanding
the commitment of precursor cells in the brain and
understanding how to express genes after the cells
have made a terminal commitment are going to be
very dramatic. In four or eight years time, when we
have these meetings, we are not even going to be
talking about transplanting fetal tissue anymore.
Fetal tissue is going to become a thing of the past
very soon and we are only going to be talking
about transplanting engineered cells.
Curt Freed:
Dr. Robbins, this has not happened yet with
kidneys, livers or hearts. I think we have to be
humble when we look at the evolution of these
wonderful dopamine cells. It will not be easy to
make our own versions of normal brain cells.
Barry Hoffer:
Are there other topics or areas the audience would
like to explore?
Larry Kromer:
I would just like to add a comment. At the end of
these meetings we always look for clinical
applications. Our discussion is usually focused on
cell replacement theories and the clinical
application of replacing degenerating neurons. I
think that there is a whole aspect of transplantation
that has a very classical history from early in the
century, and that is to understand how the nervous
system is put together, the intricate interactions
between cells, and the role of glial cells in this
interaction. I think that we should not lose our
appreciation for using transplants to understand the
nervous system and its development. We should
not always have to feel it has to have clinical
application as a primary focus.
Barry Hoffer:
Your point is very well taken. Do we have other
comments?
Paul Sanberg:
I heard the comment earlier, that perhaps in
about four or five years we won’t even be
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transplanting fetal cells. One area we need to think
about is how do you determine the "dose" of cells
to transplant? Right now we are lucky, in that we
are implanting autografts of adrenal cells, or
allografts of fetal cells. Perhaps 10% of the
mesencephalic cells that we are transplanting are
dopaminergic. However, when we start using
engineered cells, we will have very large numbers
of pure dopamine- secreting cells, or growth factor-
secreting cells. If we are successful, and we use
these cells as a cell therapy, it is not like a drug.
These cells are going to stay in there. Thus, we
really need to think about how we dose these
things. With any drug, for example, you get a
certain percentage of patients that show abnormal
responses. Some adverse responses and side effects
can be anticipated with cell transplants as well.
How do you take those cells out, how can you get
rid of them if the patient has an abnormal adverse
response? We have so far been quite lucky with
most of the clinical data. With the fetal cell grafts,
we have not seen many harmful effects, but I think
as we get into these other types of cells, it’s going
to be a real critical issue and one to think about.
Barry Hoffer:
We would like to close this discussion by
expressing our graditude to the organizers, the
audience, and all of the participants for an
enlightening and stimulating meeting. I think that
everyone has done a wonderful job. There was a lot
of effort involved in organizing this meeting, and
we want to thank all of you very much for
participating.
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